FAQ

AS1411

Known as: AS 1411, AS-1411, Anti-Nucleolin Aptamer AS1411 
A 26-base guanine-rich oligodeoxynucleotide aptamer with potential apoptotic induction activity. Upon administration, anti-nucleolin aptamer AS1411… (More)

Topic mentions per year

Topic mentions per year

1996-2018
0102019962018

Related topics

Related topics

1 relation

Broader (1)

AGRO 100

Related mentions per year

Related mentions per year

1996-2018
1990200020102020
AS1411
AGRO 100

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Targeted delivery of anticancer drugs by aptamer AS1411 mediated Pluronic F127/cyclodextrin-linked polymer composite micelles.
Aptamers are single-stranded RNA or DNA ligands that can specifically bind to various molecular targets with high affinity. Owing… (More)
  • figure 1
  • figure 2
  • table 1t1
  • figure 3
  • figure 4
Is this relevant?
2015
2015
Mechanistic studies of anticancer aptamer AS1411 reveal a novel role for nucleolin in regulating Rac1 activation.
AS1411 is a G-rich quadruplex-forming oligodeoxynucleotide that binds specifically to nucleolin, a protein found on the surface… (More)
Is this relevant?
2014
2014
Nucleolin-targeting liposomes guided by aptamer AS1411 for the delivery of siRNA for the treatment of malignant melanomas.
BRAF gene mutation is found in more than 60% of malignant melanomas, which are difficult to treat. In this study, a new tumor… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2013
2013
Nucleolin targeting AS1411 modified protein nanoparticle for antitumor drugs delivery.
Over recent years, cell surface nucleolin as an anticancer target has attracted many researchers' attentions. To improve the… (More)
Is this relevant?
2012
2012
AS1411 aptamer tagged PLGA-lecithin-PEG nanoparticles for tumor cell targeting and drug delivery.
Liposomes and polymers are widely used drug carriers for controlled release since they offer many advantages like increased… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2011
Highly Cited
2011
Aptamer-functionalized PEG-PLGA nanoparticles for enhanced anti-glioma drug delivery.
Targeted delivery of therapeutic nanoparticles in a disease-specific manner represents a potentially powerful technology… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • table 2
Is this relevant?
Highly Cited
2010
Highly Cited
2010
A new paradigm for aptamer therapeutic AS1411 action: uptake by macropinocytosis and its stimulation by a nucleolin-dependent mechanism.
AS1411 is a first-in-class anticancer agent, currently in phase II clinical trials. It is a quadruplex-forming… (More)
Is this relevant?
2009
2009
Plasma membrane nucleolin is a receptor for the anticancer aptamer AS1411 in MV4-11 leukemia cells.
AS1411 is a DNA aptamer that is in phase II clinical trials for relapsed or refractory acute myeloid leukemia and for renal cell… (More)
  • figure 2
  • figure 1
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2008
Highly Cited
2008
The nucleolin targeting aptamer AS1411 destabilizes Bcl-2 messenger RNA in human breast cancer cells.
We sought to determine whether nucleolin, a bcl-2 mRNA-binding protein, has a role in the regulation of bcl-2 mRNA stability in… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2007
Highly Cited
2007
AS1411 alters the localization of a complex containing protein arginine methyltransferase 5 and nucleolin.
AS1411 is a quadruplex-forming oligonucleotide aptamer that targets nucleolin. It is currently in clinical trials as a treatment… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?